Table 2.
Use of antiparkinsonian medications before and during LCIG at each visit
| Antiparkinsonian medications | Before LCIG start (N = 145) | Visit 1 (N = 145) | Visit 2 (N = 129) | Visit 3 (N = 115) | ||||
|---|---|---|---|---|---|---|---|---|
| N (%) | Daily dose (mg) mean ± SD | N (%) | Daily dose(mg) mean ± SD | N (%) | Daily dose (mg), mean ± SD |
N (%) | Daily dose (mg) mean ± SD | |
| Oral levodopa | 140 (96.6%) | 818.74 ± 404.4 |
5 (3%)—during the day 34 (23%)—at night |
150.0 ± 70.7 during the day 160.3 ± 72.5 at night |
4 (3%)—during the day 30 (23%)—at night |
475.0 ± 518.8 during the day 164.2 ± 56.3 at night |
4 (3%)—during the day 30 (26%)—at night |
137.5 ± 75.0 during the day 186.7 ± 73.0 at night |
| Dopamine agonists | 93 (64.1%) | 6.38 ± 5.6 | 42 (29%) | 5.6 ± 3.8 | 39 (30%) | 5.1 ± 3.3 | 28 (24%) | 6.6 ± 5.6 |
| COMT inhibitors | 64 (44.1%) | 590.7 ± 337.4 | 16 (11%) | 253.1 ± 105.6 | 16 (12%) | 215.6 ± 67.6 | 14 (12%) | 196.4 ± 69.2 |
| MAO inhibitors | 21 (14.5%) | 2.33 ± 3.31 | 5 (3%) | 3.6 ± 3.9 | 5 (4%) | 5.8 ± 5.07 | 5 (4%) | 3.6 ± 3.9 |
| Amantadine | 25 (17.2%) | 190.6 ± 112.6 | 8 (6%) | 237.5 ± 91.6 | 12 (9%) | 200.0 ± 95.3 | 10 (9%) | 220.0 ± 113.5 |
Data presented in mean ± standard deviation (SD) or number (%)
LCIG levodopa/carbidopa intestinal gel, PD Parkinson’s disease, SC subcutaneous